Investigation Effectiveness Drives Human Performance Excellence
Are investigations supporting or hindering performance excellence?
Every biopharm company conducts investigations for undesirable outcomes related to safety, quality, and reliability of product and processes. The question is to what degree do these investigations support or hinder performance excellence?
A sub-team that was formed as part of the BioPhorum Operations Group (BPOG) human performance workstream sought to answer this question. The findings suggest that biopharm is behind other industries with respect to investigation best practices.
This article provides a pathway for the industry to improve its investigations, and in so doing, improve overall organizational learning and performance.
Download Pharmaceutical Technology’s
2016 Quality Throughout the Supply Chain eBook.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
